Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study
Top Cited Papers
Open Access
- 6 December 2021
- journal article
- research article
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 10
Abstract
Background: Lipid metabolism plays an important role in viral infections. We aimed to assess the causal effect of lipid-lowering drugs (HMGCR inhibitiors, PCSK9 inhibitiors, and NPC1L1 inhibitior) on COVID-19 outcomes using two-sample Mendelian randomization (MR) study.Methods: We used two kinds of genetic instruments to proxy the exposure of lipid-lowering drugs, including expression quantitative trait loci of drugs target genes, and genetic variants within or nearby drugs target genes associated with low-density lipoprotein (LDL cholesterol from genome-wide association study). Summary-data-based MR (SMR) and inverse-variance-weighted MR (IVW-MR) were used to calculate the effect estimates.Results: SMR analysis found that a higher expression of HMGCR was associated with a higher risk of COVID-19 hospitalization (odds ratio [OR] = 1.38, 95% confidence interval [CI] = 1.06–1.81). Similarly, IVW-MR analysis observed a positive association between HMGCR-mediated LDL cholesterol and COVID-19 hospitalization (OR = 1.32, 95% CI = 1.00–1.74). No consistent evidence from both analyses was found for other associations.Conclusions: This two-sample MR study suggested a potential causal relationship between HMGCR inhibition and the reduced risk of COVID-19 hospitalization.Funding: Start-up Fund for high-level talents of Fujian Medical University.Keywords
All Related Versions
Funding Information
- Start-up Fund for high-level talents of Fujian Medical University (XRCZX2021026)
This publication has 22 references indexed in Scilit:
- The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemicEuropean Journal of Human Genetics, 2020
- Lipid lowering and Alzheimer disease risk: A mendelian randomization studyAnnals of Neurology, 2019
- PCSK9 inhibitors: clinical evidence and implementationNature Reviews Cardiology, 2018
- Reading Mendelian randomisation studies: a guide, glossary, and checklist for cliniciansBMJ, 2018
- Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseasesNature Genetics, 2018
- Interpreting findings from Mendelian randomization using the MR-Egger methodEuropean Journal of Epidemiology, 2017
- Integration of summary data from GWAS and eQTL studies predicts complex trait gene targetsNature Genetics, 2016
- Discovery and refinement of loci associated with lipid levelsNature Genetics, 2013
- Avoiding bias from weak instruments in Mendelian randomization studiesInternational Journal of Epidemiology, 2011
- Measuring inconsistency in meta-analysesBMJ, 2003